



Christopher L. Bowlus, M.D.

Philosophy of Care	Technology has led to tremendous improvements in the care of patients, but the physician's greatest tool remains the ability to listen.
Clinical Interests	Christopher L. Bowlus specializes in autoimmune liver diseases, specifically primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. He also cares for patients with hepatitis B.
Research/Academic Interests	Dr. Bowlus is interested in elucidating the underlying genetic and immunologic causes of autoimmune liver diseases and using this information to develop more effective treatments for these conditions.
Title	Division Chief of Gastroenterology and Hepatology Professor
Specialty	Gastroenterology and Hepatology, Internal Medicine
Department	Internal Medicine UC Davis Medical Group
Division	Gastroenterology and Hepatology
Clinic	UC Davis Medical Group, Sacramento - Midtown
Center/Program Affiliation	UC Davis Medical Group
Address/Phone	UC Davis Midtown Ambulatory Care Center, Midtown GI Clinic, 3160 Folsom Blvd Suite 3500 Sacramento, CA 95816 Phone: 916-734-0779
Additional Phone	Clinic Fax: 916-734-0804 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., St. Louis University School of Medicine, St. Louis, Missouri, 1990 B.A., UC San Diego, San Diego CA 1985
Internships	Internal Medicine, UC Davis Medical Center, Sacramento CA 1990-1993
Residency	Internal Medicine, UC Davis Medical Center, Sacramento CA 1991-1993
Fellowships	Gastroenterology and Hepatology, Yale University School of Medicine, New Haven CT 1993-1996
Board Certifications	American Board of Internal Medicine, 2003 American Board of Internal Medicine, Gastroenterology and Hepatology, 2009



Christopher L. Bowlus, M.D.

Professional Memberships

American Association for the Study of Liver Diseases
American College of Physicians
American Gastroenterology Association

Honors and Awards

American Liver Foundation, Postdoctoral Fellowship Award, 1994

Select Recent Publications

Bowlus CL. Primary sclerosing cholangitis: One disease or several? *Clinical Liver Disease*, 2014;3(2): 34-37.

Floreani A, Franceschet I, Perini L, Cazzagon N, Gershwin ME, Bowlus CL. New therapies for primary biliary cirrhosis. *Clin Rev Allergy Immunol*. 2015 Jun;48(2-3):263-72.

Zhang J, Zhang W, Leung PS, Bowlus CL, Dhaliwal S, Coppel RL, Ansari AA, Yang GX, Wang J, Kenny TP, He XS, Mackay IR, Gershwin ME. Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. *Hepatology*, 2014;60(5): 1708-16.

Floreani A, Franceschet I, Perini L, Cazzagon N, Gershwin ME, Bowlus CL. Therapies for Primary Biliary Cirrhosis. *Clin Rev Allergy Immunol*. 2014.

Yimam KK, Bowlus CL. Diagnosis and classification of primary sclerosing cholangitis. *Autoimmun Rev.*, 2014;13(4-5): 445-450.

Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. *Autoimmun Rev*, 2014;13(4-5): 441-444.

Yang CY, Ma X, Tsuneyama K, Huang S, Takahashi T, Chalasani NP, Bowlus CL, Yang GX, Leung PS, Ansari AA, Wu L, Coppel R, Gershwin ME. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: Implications for therapy. *Hepatology*, 2014;59(5): 1944-53.



Christopher L. Bowlus, M.D.

Tanaka H, Yang G, Iwakashi N, Knechtle S, Kawata K, Tsuneyama K, Leung P, Coppel R, Ansari A, Joh T, Bowlus C, Gershwin ME. Anti- CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. *Clinical and Experimental Immunology*, 2013;174(3): 364-71.

Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, Andreassen OA, Weersma RK, Weismüller TJ, Eksteen B, Invernizzi P, Hirschfield GM, Gotthardt DN, Pares A, Ellinghaus D, Shah T, Juran BD, Milkiewicz P, Rust C, Schramm C, Müller T, Srivastava B, Dalekos G, Nöthen MM, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen CY, Croucher PJ, Sterneck M, Teufel A, Mason AL, Saarela J, Leppä V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich SS, Thompson WK, Schork AJ, Næss S, Thomsen I, Mayr G, König IR, Hveem K, Cleynen I, Gutierrez-Achury J, Ricaño-Ponce I, van Heel D, Björnsson E, Sandford RN, Durie PR, Melum E, Vatn MH, Silverberg MS, Duerr RH, Padyukov L, Brand S, Sans M, Annese V, Achkar JP, Boberg KM, Marschall HU, Chazouillères O, Bowlus CL, Wijmenga C, Schrumpf E, Vermeire S, Albrecht M; UK-PSCSC Consortium; International IBD Genetics Consortium, Rioux JD, Alexander G, Bergquist A, Cho J, Schreiber S, Manns MP, Färkkilä M, Dale AM, Chapman RW, Lazaridis KN; International PSC Study Group, Franke A, Anderson CA, Karlsen TH. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics*, 2013;45(6): 670-675.

Chen MS Jr, Fang DM, Stewart SL, Ly MY, Lee S, Dang JH, Nguyen TT, Maxwell AE, Bowlus CL, Bastani R, Nguyen TT. Increasing hepatitis B screening for Hmong adults: results from a randomized controlled community-based study. *Cancer Epidemiology, Biomarkers & Prevention*, 2013;22(5): 782-91.

Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, Awad A, Hirschfield GM, Milkiewicz P, Bloch DB, Rothschild KJ, Bowlus CL, Adamopoulos IE, Leung PS, Janssen HJ, Cheung AC, Coltescu C, Gershwin ME. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. *Liver Int.* 2014.

© 2021 UC Regents